• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Maher Illya Keith

    10/22/21 7:45:39 AM ET
    $CERC
    Major Pharmaceuticals
    Health Care
    Get the next $CERC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Maher Illya Keith

    (Last) (First) (Middle)
    C/O AVALO THERAPEUTICS, INC.
    540 GAITHER ROAD, SUITE 400

    (Street)
    ROCKVILLE MD 20850

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/15/2021
    3. Issuer Name and Ticker or Trading Symbol
    Avalo Therapeutics, Inc. [ AVTX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned.
    /s/ Illya Keith Maher 10/22/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CERC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CERC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Maher Illya Keith

      3 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      10/22/21 7:45:39 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Bruhn Suzanne Louise

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      10/4/21 4:48:25 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Gutry Phil

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      10/4/21 4:45:42 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.

      Name change underscores the Company's transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseasesRobust pipeline of six product candidates advancing in development with eight ongoing clinical programsFour therapies with Rare Pediatric Disease Designation with each potentially eligible for a Priority Review Voucher upon approvalMultiple data readouts anticipated in the second half of 2021 WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significa

      8/26/21 7:30:00 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates

      Announced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsAnnounced plans to explore CERC-002 in patients with moderate-to-severe ulcerative colitis refractory to anti-TNF alpha therapiesCompleted $35 million debt financing that extends cash runway and supports multiple clinical catalysts anticipated in the second half of 2021 ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of tre

      8/2/21 4:01:00 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance

      ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced that it has completed its second drawdown of $10 million under its previously announced $35 million debt financing agreement with Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon"). This second tranche was made available in connection with the Company's successful positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002, an investigational first-in-class fully huma

      8/2/21 7:30:00 AM ET
      $CERC
      $HRZN
      Major Pharmaceuticals
      Health Care
      Finance: Consumer Services
      Finance

    $CERC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Cerecor Inc. (Amendment)

      SC 13D/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      10/14/21 9:01:02 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Cerecor Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      9/21/21 4:51:43 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Cerecor Inc. (Amendment)

      SC 13D/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      9/17/21 3:04:41 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Cerecor with a new price target

      Cantor Fitzgerald initiated coverage of Cerecor with a rating of Overweight and set a new price target of $7.00

      6/4/21 7:42:32 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor upgraded by Maxim Group with a new price target

      Maxim Group upgraded Cerecor from Hold to Buy and set a new price target of $7.00

      4/21/21 9:51:06 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Jefferies initiated coverage on Cerecor with a new price target

      Jefferies initiated coverage of Cerecor with a rating of Buy and set a new price target of $4.00

      4/20/21 7:17:47 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    SEC Filings

    See more

    $CERC
    Financials

    Live finance-specific insights

    See more

    $CERC
    Leadership Updates

    Live Leadership Updates

    See more
    • Cerecor Inc. filed SEC Form 8-K: Leadership Update

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      10/18/21 4:11:35 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      9/15/21 4:44:34 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form 424B5 filed by Cerecor Inc.

      424B5 - Avalo Therapeutics, Inc. (0001534120) (Filer)

      9/15/21 4:41:54 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients

      Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsMean reduction in LIGHT levels of approximately 80% compared to baseline signify a dramatic and rapid reduction of LIGHT levels correlating to the pharmacodynamic effect of CERC-002Clinically meaningful endoscopic improvement in 75% (3/4) of subjects, as determined by colonoscopy (SES-CD score)CERC-002 was well tolerated with no drug-related severe adverse eventsCohort 2 (3.0 mg/kg dose) fully enrolled; complete data anticipated in 2H21Promising initial results support expansion to p

      7/26/21 4:01:00 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Panbela Appoints Industry Veteran, Garry A. Weems, PharmD, as Vice President of Clinical Development & Medical Affairs

      MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced the appointment of Garry A. Weems, PharmD, as its Vice President of Clinical Development and Medical Affairs. Dr. Weems joins Panbela from Cerecor, Inc. (Nasdaq:CERC) where he was Senior Director of Clinical Development. “Panbela has made considerable progress in the last 12-months and is now at a critical juncture as we begin to plan more expansive development of SBP-101,” said Jennifer Simpson, Chief Executive Officer at Panbela. “Garry’s substantial backgroun

      3/15/21 8:00:00 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Appoints Schond L. Greenway as Chief Financial Officer

      ROCKVILLE, Md. and CHESTERBROOK, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced the appointment of Schond L. Greenway as Chief Financial Officer, effective March 1, 2021. Mr. Greenway comes to Cerecor with over 20 years’ experience in investment banking, finance and corporate advisory and investment analysis in the life sciences and financial services industries. Chris Sullivan, who has served as the Company’s Interim Chief Financial Officer for the past year, will continue with the Company as its Chief Accounting

      3/1/21 7:00:00 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care